Compare Incyte Corporation (INCY) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Incyte Corporation trades at $118.01 (market cap $23.11B), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.19. The key difference: Incyte Corporation is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| INCY | SPHD | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | — |
52-Week High | $118.52 | $53.18 |
52-Week Low | $67.38 | $46.96 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SPHD trades at $52.39, down 0.91% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering a 4.5% yield with monthly distributions. Recent news highlights its defensive appeal for retirees seeking stable income amid market uncertainty, though it has underperformed the broader S&P 500 historically.
Outlook remains cautious; SPHD provides income stability but faces growth limitations. Risks include interest rate sensitivity and sector concentration. Analyst sentiment is mixed, with upgrades citing defensive positioning but noting long-term performance gaps versus the market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
